Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study

BACKGROUND: We aimed to investigate the effectiveness of omalizumab, a monoclonal anti-immunoglobulin E antibody, in Chinese patients with moderate-to-severe allergic asthma in real-world clinical practice. METHODS: This single-centre, prospective, observational study included Chinese patients aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wen, Li, Jieying, Zou, Congying, Zhao, Lifang, Zhu, Ya, Guo, Yue, Wang, Feiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514615/
https://www.ncbi.nlm.nih.gov/pubmed/37734750
http://dx.doi.org/10.1136/bmjresp-2022-001549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514615/
https://www.ncbi.nlm.nih.gov/pubmed/37734750
http://dx.doi.org/10.1136/bmjresp-2022-001549

Ejemplares similares